CCIA
PVLA

Campbell & Co Investment Adviser’s Palvella Therapeutics PVLA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-181
Closed -$81K – 538
2018
Q3 		$81K Buy
+181
New +$78.7K 0.06% 379

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Campbell & Co Investment Adviser's PVLA Position: Q4 2018 in Review

Campbell & Co Investment Adviser sold out of Palvella Therapeutics (PVLA) in Q4 2018, closing a stake of 181 shares — an estimated $81K sold.

Campbell & Co Investment Adviser first reported a position in PVLA in Q3 2018 and held it in 1 quarter. The position peaked at $81K in Q3 2018. 98 funds tracked by Wall St. Rank hold PVLA as of Q4 2018.

  • Campbell & Co Investment Adviser reported no remaining Palvella Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 181 Palvella Therapeutics shares in Q4 2018, an estimated $81K.
  • Campbell & Co Investment Adviser first reported a position in Palvella Therapeutics in Q3 2018 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Palvella Therapeutics position peaked at $81K in Q3 2018.
  • 98 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2018.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2018, filed 8 Feb 2019.